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ABSTRACT: Mitragyna speciosa, more commonly known as kratom, is a plant native to Southeast Asia, the leaves of which
have been used traditionally as a stimulant, analgesic, and treatment for opioid addiction. Recently, growing use of the plant in
the United States and concerns that kratom represents an uncontrolled drug with potential abuse liability, have highlighted the
need for more careful study of its pharmacological activity. The major active alkaloid found in kratom, mitragynine, has been
reported to have opioid agonist and analgesic activity in vitro and in animal models, consistent with the purported eﬀects of
kratom leaf in humans. However, preliminary research has provided some evidence that mitragynine and related compounds
may act as atypical opioid agonists, inducing therapeutic eﬀects such as analgesia, while limiting the negative side eﬀects typical
of classical opioids. Here we report evidence that an active metabolite plays an important role in mediating the analgesic eﬀects
of mitragynine. We ﬁnd that mitragynine is converted in vitro in both mouse and human liver preparations to the much more
potent mu-opioid receptor agonist 7-hydroxymitragynine and that this conversion is mediated by cytochrome P450 3A
isoforms. Further, we show that 7-hydroxymitragynine is formed from mitragynine in mice and that brain concentrations of this
metabolite are suﬃcient to explain most or all of the opioid-receptor-mediated analgesic activity of mitragynine. At the same
time, mitragynine is found in the brains of mice at very high concentrations relative to its opioid receptor binding aﬃnity,
suggesting that it does not directly activate opioid receptors. The results presented here provide a metabolism-dependent
mechanism for the analgesic eﬀects of mitragynine and clarify the importance of route of administration for determining the
activity of this compound. Further, they raise important questions about the interpretation of existing data on mitragynine and
highlight critical areas for further research in animals and humans.
■ INTRODUCTION
Mitragyna speciosa, often referred to by the common name
kratom, is an evergreen tree native to the tropical jungles of
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Southeast Asia, where it has been used for at least the last
century as a traditional medicine. In its native regions, leaves of
the kratom tree are typically consumed as a tea or chewed
directly, and are purported to induce stimulant and opioid-like
analgesic eﬀects in the user in a dose- and time-dependent
manner. These eﬀects have traditionally made kratom popular
among agricultural workers, who use the plant to aid in long
hours of hard labor. Kratom has also been reported to be useful
in ameliorating withdrawal symptoms following cessation of
opioid use, and it has achieved some popularity for this use in
its native regions.1−8
Over the past decade, kratom use has become increasingly
popular in the United States (US). Many thousands of US
users have reported that consumption of kratom preparations
(most often in the form of dried, powdered leaf material) is an
eﬃcacious treatment not only for physical pain, but also for
mood and anxiety disorders, particularly in cases where other
available treatments have either failed or elicited intolerable
side eﬀects.9−13 A signiﬁcant portion of users have also
reported use of kratom as a tool to stop or reduce consumption
of prescription or illicit opioids, a potential application that is
presently of high interest given the ongoing opioid abuse
epidemic in the US. Unfortunately, there have been no
controlled clinical studies either examining these alleged
therapeutic eﬀects or quantifying any potential risks of kratom
use. At the same time, kratom is primarily distributed through
unregulated Internet sales and used outside medical super-
vision. Considering these factors, as well as the reported
opioid-like eﬀects and adverse health eﬀects of the plant, the
US Drug Enforcement Administration (DEA) and the US
Food and Drug Administration (FDA) have both raised
concerns that kratom represents a potential drug of abuse and
public health threat.14−16 In September 2016, the DEA
announced its intent to place the active compounds found in
kratom into Schedule I of the Controlled Substances Act but
ultimately decided not to proceed with this action following a
large public outcry from the kratom user community, including
over 23 000 comments logged in the federal register docket for
this issue.13,17−19 Despite this turn of events, kratom at this
time remains in regulatory limbo, with an uncertain future in
the US. Accordingly, our laboratories have been working to
develop a preclinical proﬁle of kratom’s biological eﬀects, with
the hope that such knowledge will prove useful for the
development of future therapeutics based on kratom, as well as
guide regulatory decision making on the plant itself.
Kratom contains a number of indole alkaloids that are
believed to be the primary contributors to its psychoactive
eﬀects. Chief among these is mitragynine (Figure 1), which
typically constitutes 1−2% of the dry leaf mass and up to
approximately two-thirds of the total alkaloid content.1,5 This
compound is joined by 7-hydroxymitragynine (7-OH, Figure
1) in much lower concentrations, typically less than 0.05% of
the dried leaf mass.1,20 The other predominant alkaloids found
in kratom leaf are speciogynine, speciociliatine, and paynan-
theine (each ∼0.2−0.5% of dry leaf mass), but at this time little
is known about their pharmacology.1,5
We have reported that mitragynine and 7-OH are partial
agonists of the human μ-opioid receptor (hMOR) in vitro,
with 7-OH (EC50 = 34.5 nM; Emax = 47%) being ∼10-fold
more potent than mitragynine (EC50 = 339 nM; Emax =
34%).21 Further, both compounds are known to exhibit opioid-
receptor-dependent analgesic eﬀects in rodent models, with 7-
OH again being signiﬁcantly more potent.6,22−25 At the same
time, we have also found that both mitragynine and 7-OH are
G protein-biased agonists of the mu-opioid receptor
(MOR).21,25 We have thus classiﬁed the kratom alkaloids as
“atypical opioids” and have postulated that these compounds
may provide a greater therapeutic window between analgesia
and classical opioid side eﬀects. For example, other MOR
agonists that activate G protein signaling without recruiting the
beta-arrestin pathway exhibit attenuated respiratory depression
and reduced inhibition of gastrointestinal (GI) transit
compared to classical opioids.26−30 In fact, an early study on
the pharmacology of mitragynine demonstrated its superiority
compared to the classical opioid codeine in this regard,
providing preliminary support for this hypothesis.24 Similarly,
mitragynine pseudoindoxyl, a chemical rearrangement product
of 7-OH, has been found to be both G-protein biased and
exhibit an improved therapeutic window in mice.25
Both methanolic and crude alkaloid extracts of kratom have
also demonstrated analgesic properties in rodents.1 However, it
currently remains unsettled which of kratom’s alkaloids are the
most important contributors to the analgesic properties of such
preparations or to those of the raw leaf. Despite its higher
potency, we previously estimated on the basis of preclinical
studies that the quantity of 7-OH contained in typical dry
kratom leaf preparations is insuﬃcient to induce opioid-like
eﬀects directly at typical doses consumed by human subjects.1
At the same time, examination of the existing literature on the
pharmacology of mitragynine revealed a number of unusual
Figure 1. Known (Pathway A) and proposed (Pathway B) metabolic transformations of mitragynine.
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observations that complicated our understanding at the outset
of the present investigations. First, despite low to moderate
oral bioavailability (20−30% in rats), mitragynine has been
found in prior investigations to be paradoxically more potent as
an analgesic when administered by the oral (p.o.) and
intraperitoneal (i.p.) routes compared to the subcutaneous
(s.c.) route in rats and mice.1,24,31 These ﬁndings suggested to
us the involvement of an active metabolite produced via ﬁrst-
pass metabolism in mediating the analgesic activity of
mitragynine.1 At the same time, our own prior in vitro studies
at the mouse mu-opioid receptor (mMOR) had shown that
mitragynine acts as either a competitive antagonist or a partial
agonist depending on the assay system used, calling into
question the ability of this compound to have a direct agonist
eﬀect on MOR in rodents and consistent with a metabolite-
driven analgesic eﬀect.21,25 However, mitragynine has also
been found to induce analgesic eﬀects when administered
intracerebroventricularly (i.c.v), which argued conversely
against the involvement of an active metabolite (unless
metabolism occurs directly in the brain).23 Therefore, we set
out to further elucidate the pharmacological and metabolic
mechanism(s) leading to mitragynine’s analgesic eﬀects.
■ RESULTS
Known Metabolites Do Not Explain Analgesic
Activity. Given our working hypothesis that an active
metabolite might be involved in mediating the analgesic
eﬀects of mitragynine, we were interested in identifying
metabolites that might exhibit agonist activity at MOR. The
metabolites of mitragynine in rat and human urine had been
previously studied, revealing a large number of metabolites
modiﬁed primarily through demethylation at one or more of
mitragynine’s three O-methyl groups (Figure 1, Pathway A),
followed by either glucuronidation or sulfation of the exposed
nucleophile, or oxidative or reductive transformations of the
acrylate moiety.32 Considering previously observed structure−
activity relationships (SAR) in the mitragynine scaﬀold, it was
expected that the demethylated metabolites would exhibit
similar or lower potency activity at MOR compared to
mitragynine.21 This was conﬁrmed by synthesis of these
compounds and testing using in vitro functional assays at
hMOR (see Supporting Information, Table S1). Similarly,
conjugated metabolites were also expected to be both inactive
at MOR and have low penetration of the blood−brain barrier
(BBB). Accordingly, when we began our investigation, known
metabolites were insuﬃcient to explain the opioid-mediated
analgesic activity of mitragynine.
Deuteration of Mitragynine Has Little Eﬀect on
Metabolism in Vitro. Our above supposition was further
strengthened by ﬁndings with a deuterated analogue. On the
basis of the reported metabolic pathways of mitragynine, we
synthesized an analogue of this compound fully deuterated at
each of its three O-methyl groups, mitragynine-d9 (see
Supporting Information, Scheme S1), expecting that, through
kinetic isotope eﬀects, the metabolism of this derivative would
be slowed. Surprisingly, when we examined the stability of
mitragynine-d9 head-to-head with its undeuterated counterpart
in human liver microsomes (HLM) and mouse liver
microsomes (MLM), stability was unchanged (Figure 2A).
Therefore, we concluded that demethylation is only a minor
pathway of hepatic metabolism (demethylated metabolites
may accumulate slowly in the urine or be formed extrahepati-
cally) and that the previously reported metabolites are unlikely
to explain the hypothesized role of a hepatically formed
metabolite in the analgesic activity of mitragynine.
Chemistry Suggests a New Site of Metabolism. With
known metabolites seemingly unable to explain the observa-
tions pointing toward an active metabolite, we began exploring
alternative metabolic pathways that might yield such a
compound. For inspiration, we turned to known chemical
transformations of indole alkaloids, including mitragynine,
under oxidative conditions. For example, 2,3-disubstituted
indoles are known to undergo functionalization under
oxidation/halogenation conditions to aﬀord the corresponding
3-substituted indolenines.33 Speciﬁcally, mitragynine is known
to be oxidized by [bis(triﬂuoroacetoxy)iodo]benzene (PIFA)
to give 7-OH (Scheme 1).6 During our ongoing synthetic
explorations of the mitragynine scaﬀold, we also found that
singlet oxygen21 and potassium peroxymonosulfate (Oxone)
were eﬀective oxidants for the conversion of mitragynine into
7-OH (Scheme 1). Therefore, we postulated that the 2−3
indole double bond attacked by these chemical oxidants might
also be a site for oxidation by cytochrome P450 enzymes
(CYPs) to produce 7-OH as a metabolite (Figure 1, Pathway
B). Given the much greater potency of 7-OH as an MOR
agonist, we hypothesized that even minor conversion to this
product might contribute signiﬁcantly to mitragynine’s
analgesic activity and help to explain the apparent contra-
dictions in the literature.
Figure 2. Decomposition of mitragynine and formation of 7-OH in liver microsomes was quantiﬁed by LC-MS/MS. (A) Mitragynine was unstable
in both MLM and HLM, while deuteration of all three methyl groups, as in mitragynine-d9, had little eﬀect on microsomal stability. (B) Loss of
mitragynine in microsomal preparations was accompanied by formation of 7-OH as a metabolite, and this conversion was more eﬃcient in HLM.
There was a strong main eﬀect of species on 7-OH concentration. Two-way ANOVA: F1,30 = 51.66, p < 0.0001. ****p < 0.0001 relative to MLM,
**p < 0.01 relative to MLM, *p < 0.05 relative to MLM, ns = p > 0.05 relative to MLM. All data points represent the means of two independent
experiments with two incubations per experiment, with error bars representing ± SEM.
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7-OH is a Mitragynine Metabolite in Vitro. To test our
hypothesis, we monitored formation of 7-OH by liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
during incubation of mitragynine with both HLM and MLM.
In both microsome preparations, 7-OH was produced
concomitant with disappearance of mitragynine (Figure 2B).
Further, 7-OH appeared to be the major metabolite in each
case, as the approximate decreases in molar mitragynine
concentration from the starting level (2 μM) were accom-
panied by similar increases in 7-OH concentration. The
metabolic conversion was more eﬃcient in HLM, suggesting
that an appreciation of interspecies diﬀerences is likely to be
important for understanding the pharmacology of mitragynine.
However, note that our ﬁndings conﬂict with an earlier report,
which found that mitragynine was stable in microsomes.34 The
reason for this discrepancy remains unclear at this time, but it
may relate to variable metabolic activity of microsome
preparations from diﬀerent sources. Further, we conﬁrmed
the low stability of mitragynine in HLM and concomitant
formation of 7-OH in an independent laboratory (Biotranex,
LLC, data not shown).
7-OH is Resistant to Phase I Metabolism. Having found
that 7-OH was indeed formed from mitragynine in vitro, we
next assessed whether this compound was itself stable in liver
preparations. We found that 7-OH was stable in both HLM
and MLM, with more than 90% remaining after 40 min of
incubation (Figure S1). This ﬁnding that 7-OH was stable to
oxidative Phase I metabolism was consistent with its
accumulation during microsomal incubations of mitragynine.
Mitragynine and 7-OH are Stable in Plasma. Before
proceeding further, we also tested the stability of mitragynine
and 7-OH in blood plasma. Both mitragynine and 7-OH were
highly stable in mouse plasma (Figure S2), indicating that
plasma hydrolysis or other plasma metabolism does not
contribute signiﬁcantly to the biotransformation of these
compounds.
Conversion of Mitragynine to 7-OH is Mediated by
CYP3A Isoforms in Vitro. We next set out to determine
which CYP isoform is responsible for conversion of
mitragynine to 7-OH. Mitragynine was incubated in vitro
with puriﬁed recombinant preparations of the ﬁve major
human CYP isoforms (CYP3A4, 2C19, 2C9, 1A2, 2D6)
alongside a reference substrate of each isoform as positive
control. Decomposition of mitragynine was nearly complete in
the presence of CYP3A4 (2% remaining at 60 min). In
contrast, there was little or no decomposition in the
incubations with CYP2C19, 2C9, 1A2, and 2D6 (77%, 99%,
96%, and 82% remaining at 60 min, respectively). The activity
of each enzyme preparation was conﬁrmed by nearly complete
disappearance of the reference substrates (Figure 3A). During
these incubations, the formation of 7-OH was also monitored
by LC-MS/MS, revealing that formation of 7-OH was most
robust in the presence of CYP3A4, whereas little conversion to
7-OH was observed in the incubations with other CYPs
(Figure 3B).
Having identiﬁed CYP3A4 as the predominant metabolic
pathway responsible for hepatic metabolism of mitragynine
and concurrent formation of 7-OH using puriﬁed enzyme
preparations, we next sought to conﬁrm these results in liver
microsomes, a more complex system with endogenous
expression of relevant enzymes. To that end, mitragynine
was incubated with HLM alone and in the presence of the
CYP3A inhibitor ketoconazole (1 or 10 μM), the CYP2C19
inhibitor ticlopidine (20 μM), or a combination of the two.
Ketoconazole robustly inhibited both decomposition of
mitragynine (Figure 4A) and formation of 7-OH (Figure
4B), whereas ticlopidine had little eﬀect. Analogous results
were found in MLM (Figure S3). In sum, our ﬁndings
Scheme 1. Conversion of Mitragynine to 7-OH by Chemical
Oxidants
Figure 3. CYP3A4 mediates conversion of mitragynine to 7-OH. (A) Mitragynine was incubated in vitro with recombinant preparations of the ﬁve
major human CYP isoforms alongside a reference substrate of each isoform as positive control. The relative percent remaining of mitragyine or
reference substrate in each incubation was quantiﬁed by LC-MS/MS. Disappearance of mitragynine was most rapid in the presence of CYP3A4,
whereas incubations with the other isoforms resulted in little or no decomposition. The activity of each preparation was conﬁrmed by the nearly
complete disappearance of the corresponding reference substrates. (B) Formation of 7-OH was monitored by LC-MS/MS during incubation of
mitragynine with each of the recombinant CYP preparations. CYP3A4 resulted in the most robust conversion to 7-OH. All data points represent
the means of two independent experiments with two incubations per experiment, with error bars representing ± SEM.
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demonstrate that mitragynine is converted to 7-OH in both
mouse and human liver preparations and that this conversion is
mediated by CYP3A isoforms (including CYP3A4 in humans).
Mitragynine is Analgesic in Mice Through an MOR-
Dependent Mechanism. To build on the preceding results,
we hoped to examine whether 7-OH is in fact formed as a
metabolite of mitragynine in vivo. Further, we sought to test
whether 7-OH, as a metabolite, could be a key mediator of the
analgesic eﬀects of mitragynine. However, before proceeding
with these experiments, we ﬁrst set out to conﬁrm the analgesic
activity of mitragynine in our own hands and to determine
whether these eﬀects are dependent on MOR.
For this purpose, we used the 129 mouse strain, which we
found to be sensitive to mitragynine-induced analgesia,
consistent with the documented high sensitivity of this strain
to opioid agonists.35,36 Further, genetic knockouts of opioid
receptors are available on this genetic background. Dose−
response curves were generated for mitragynine administered
by both oral (p.o.) and subcutaneous (s.c.) routes using the
tail-ﬂick test, a classic rodent model for analgesic activity
(Figure 5A). We found that mitragynine was much more
potent when administered p.o. (ED50 = 2.1 mg/kg) than when
administered s.c. (ED50 = 106 mg/kg), consistent with earlier
literature reports. To establish the opioid receptor dependence
of these eﬀects, an eﬃcacious analgesic dose of mitragynine
(10 mg/kg, p.o.) was administered to MOR knockout (KO),
κ-opioid receptor (KOR) KO, and δ-opioid receptor (DOR)
KO mice, and to wild-type (WT) mice following pretreatment
with the opioid receptor antagonist naloxone (1 mg/kg, s.c.).
Both MOR KO and naloxone pretreatment signiﬁcantly
attenuated the analgesic eﬀect of mitragynine, whereas KOR
KO and DOR KO had no eﬀect (Figure 5B). Therefore, the
analgesic activity of mitragynine was found to be MOR-
dependent, consistent with prior literature demonstrating
pharmacological blockade of analgesia with the opioid receptor
antagonist naloxone.6,23
7-OH is a Potent Analgesic in Mice Acting Through
an MOR-Dependent Mechanism. Before further exploring
our hypothesis that 7-OH is a key active metabolite of
mitragynine, we also wanted to conﬁrm the potent analgesic
activity reported for this compound. A dose−response curve
was generated for 7-OH in 129 mice using the tail-ﬂick assay
(Figure 5A). Consistent with previous reports,22,25 it was
found that 7-OH was a highly potent analgesic (ED50 = 0.6
mg/kg, s.c.), ∼ﬁvefold more potent than p.o. mitragynine. This
high potency was consistent with our hypothesis that 7-OH
formed as a metabolite, even in small quantities, could be
responsible for mediating much of mitragynine’s analgesic
activity. Both MOR KO and naloxone pretreatment signiﬁ-
cantly attenuated the analgesic eﬀects of 7-OH, whereas the
analgesic eﬀect was retained in KOR KO and DOR KO
animals (Figure 5C). Therefore, the analgesic activity induced
by 7-OH was also MOR dependent. We note that the reason
for the slight enhancement of analgesia in KOR KO and DOR
KO animals remains unclear, but some prior literature has
suggested that blockade of DOR may enhance MOR-
dependent analgesia.37 Further, any potential antagonism of
KOR or DOR by mitragynine or 7-OH, as has been suggested
by in vitro studies,21 would not be expected to contribute to
analgesic eﬀects directly, since antagonists of these receptors
are not known to be analgesic on their own. Thus, our ﬁndings
are consistent with agonism of MOR as the primary
mechanism of analgesia for both compounds.
Conversion of Mitragynine to 7-OH also Occurs in
Vivo. Having proﬁled the analgesic eﬀects of mitragynine and
7-OH in mice, we next set out to conﬁrm that the metabolic
conversion that we had previously observed in vitro also
occurred in living animals. Mice (129S1) were treated with
mitragynine (10 mg/kg, s.c.), and plasma and brain samples
were collected at 15 and 60 min and analyzed by LC-MS/MS
for mitragynine and 7-OH. Both mitragynine (Figure 6A) and
7-OH (Figure 6B) were detected at both time points in both
plasma and brain, conﬁrming that 7-OH is indeed formed as a
metabolite of mitragynine in vivo and that it enters the brain.
These results also permitted a preliminary assessment of the
BBB penetration of the two alkaloids by comparison of plasma
to whole brain concentrations. By this metric, mitragynine
brain penetration was very high (∼1:1 brain/plasma), whereas
7-OH brain penetration was more modest (∼1:5 brain/
plasma). However, note that this estimation does not account
for tissue binding and, thus, does not necessarily reﬂect free
concentrations of drug.
It is interesting to note the diﬀerences between our ﬁndings
in vitro in microsome preparations and those in vivo. In
microsomes, we found that 7-OH was a major hepatic
Figure 4. CYP3A-dependence of 7-OH formation was conﬁrmed in
HLM. Disappearance of mitragynine and formation of 7-OH was
monitored by LC-MS/MS. (A) In HLM, the CYP3A isoform
inhibitor ketoconazole (Ket) dose-dependently attenuated metabolic
decomposition of mitragynine. In contrast, the CYP2C19 inhibitor
ticlopidine (Tic) had little eﬀect. (B) During incubation of
mitragynine with HLM, ketoconazole (and to a small degree,
ticlopidine) also inhibited formation of 7-OH. All data points
represent the means of two independent experiments with two
incubations per experiment, with error bars representing ± SEM.
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metabolite. In contrast, in mice, 7-OH was found to be only a
minor metabolite in terms of relative concentrations, with a
mitragynine/7-OH ratio in plasma of ∼15:1 or more
(dependent on time point). This suggests both inherent
diﬀerences between the metabolic activity of in vitro and in
vivo systems, as well as additional hepatic or extrahepatic
routes of mitragynine and/or 7-OH metabolism not well
accounted for by in vitro microsome preparations.
7-OH Contributes to the Analgesic Activity of
Mitragynine as a Metabolite. Having shown that 7-OH
was indeed a metabolite of mitragynine in mice, we last
examined whether the concentration of this metabolite formed
in vivo might be suﬃcient to contribute to mitragynine’s
opioid-mediated analgesic eﬀects. To demonstrate this, we
planned an experiment in which the brain concentration of 7-
OH observed as a metabolite following administration of an
analgesic dose of mitragynine would be compared to the brain
concentration of 7-OH observed following direct adminis-
tration of an equianalgesic dose of 7-OH. Under these
conditions, we hypothesized that 7-OH concentrations would
be similar if this metabolite was in fact playing a signiﬁcant role
in mediating the analgesic eﬀects of mitragynine. In testing this
hypothesis, we chose to administer both compounds by the s.c.
route, as we found that it was diﬃcult to obtain reliable dose−
response curves for p.o. 7-OH, likely as a result of variable p.o.
absorption of the compound. Thus, s.c. administration was
necessary to allow the PK of mitragynine and 7-OH to be
compared following the same route of administration, which
was desirable from the standpoint of consistency.
Equianalgesic doses of mitragynine (140 mg/kg, s.c.) and 7-
OH (0.7 mg/kg, s.c.) were selected based on the previously
obtained dose−response curves (∼1.3-fold ED50, Figure 5A).
Mice (129S1) were treated with the selected doses, and
analgesic activity was conﬁrmed at 15 min in the tail-ﬂick assay.
As expected, there was no signiﬁcant diﬀerence in tail-ﬂick
latency between the two groups (Figure 7A). Immediately after
Figure 5. Analgesic activity of mitragynine in 129 mice. (A) Dose−responses of mitragynine and 7-OH in the tail-ﬂick assay at time of maximal
analgesic eﬀect (15 min). Mice (n = 5−17 per dose, per treatment; 129S1 strain) were treated with ascending doses of mitragynine or 7-OH by the
indicated route of administration in a cumulative dosing procedure, and tail-ﬂick latency was recorded for each animal at 15 min post drug
administration (peak analgesic eﬀect). ED50s (95% CI) were as follows: mitragynine, s.c. = 106 (57.4−195) mg/kg; mitragynine, p.o. = 2.05 (1.24−
3.38); 7-OH, s.c. = 0.57 (0.19−1.7). The means of each point were calculated as percentage maximal possible eﬀect (%MPE) [(observed latency −
baseline latency)/(maximal latency − baseline latency)] × 100. Error bars represent ± SEM. (B) The analgesic eﬀect of mitragynine (10 mg/kg,
p.o.) in the tail-ﬂick assay was evaluated 15 min post drug administration in WT, MOR-1 KO, KOR-1 KO, and DOR-1 KO mice, and WT mice
following pretreatment with naloxone (1 mg/kg, s.c.), in two independent experiments (n = 5 per group per experiment, n = 10 total per group;
129S6 strain). The analgesic eﬀect of mitragynine was attenuated by naloxone pretreatment and in MOR-1 KO, while the eﬀect was found intact in
KOR-1 KO and DOR-1 KO mice. One-way ANOVA: F4,45 = 19.90, p < 0.0001. ****p < 0.0001 relative to WT, ns = p > 0.05 relative to WT. All
values are expressed as the mean ± SEM. (C) The analgesic eﬀect of 7-OH (1 mg/kg, s.c.) in the tail-ﬂick assay was evaluated 15 min post drug
administration in WT, MOR-1 KO, KOR-1 KO, and DOR-1 KO mice, and WT mice following pretreatment with naloxone (1 mg/kg, s.c.), in two
independent experiments (n = 5 per group per experiment, n = 10 total per group; 129S6 strain). The analgesic eﬀect of 7-OH was attenuated by
naloxone pretreatment and in MOR-1 KO, while the eﬀect was found intact in KOR-1 KO and DOR-1 KO mice. One-way ANOVA: F4,45 = 101.7,
p < 0.0001. ****p < 0.0001 relative to WT, *p < 0.05 relative to WT. All values are expressed as the mean ± SEM.
Figure 6. Conversion of mitragynine to 7-OH was conﬁrmed in vivo in 129S1 mice using LC-MS/MS. (A) Mitragynine was detected in both the
plasma and brains of mice treated with mitragynine (10 mg/kg, s.c.). n = 4 per time point for plasma; n = 8−9 per time point for brain. (B) At the
same time, 7-OH was also detected in the plasma and brains of the same animals, but at lower concentrations.
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determination of tail-ﬂick latency, mice were sacriﬁced, and
brain samples were collected for analysis. There was no
signiﬁcant diﬀerence in the mean brain concentration of 7-OH
found in the mitragynine group (formed as metabolite)
compared to that found in the 7-OH group (from direct
administration) (Figure 7B), consistent with 7-OH being the
primary mediator of central analgesic activity in both cases. At
the same time, very brain high concentrations (16.6 ± 2.7 μM;
mean ± standard error of the mean (SEM)) of mitragynine
were observed in the mitragynine-treated animals, while
minimal concentrations (0.097 ± 0.012 μM; mean ± SEM)
were observed in the 7-OH-treated animals (Figure 7C). This
170-fold diﬀerence in mitragynine brain concentration
between the two groups had no signiﬁcant eﬀect on analgesia
(Figure 7A), despite the fact that the mitragynine brain
concentration in the mitragynine-treated group was ∼50-fold
higher than the compound’s binding aﬃnity for mMOR (0.23
μM21). Accordingly, we conclude that 7-OH formed as a
metabolite is suﬃcient to explain the opioid-mediated
analgesic activity of mitragynine and that the parent compound
does not make a signiﬁcant contribution to its own analgesic
activity in mice.
Although it does not appear to play an important role in
mediating analgesia, the above observation of small quantities
of mitragynine formed as a metabolite of 7-OH in vivo was
surprising to us. We did not expect to observe this reductive
metabolic process, which is eﬀectively the reverse of the
observed oxidative metabolism of mitragynine to 7-OH.
However, prior literature had indeed reported the partial
conversion of 7-OH to mitragynine in vitro in liver
microsomes and simulated gastric ﬂuid.34 The exact mecha-
nism of this transformation remains unclear at this time.
■ DISCUSSION
In the present report, we provide evidence that hepatic
formation of 7-OH as a metabolite is important in mediating
the analgesic activity (and presumably other MOR-mediated
eﬀects) of mitragynine, the major active alkaloid of the kratom
plant. The analgesic eﬀects of mitragynine and 7-OH each
depended on activation of MORs. Further, the analgesia
induced by mitragynine appears to depend largely on
formation of 7-OH as a metabolite and not on the parent
compound. Accordingly, the pharmacological proﬁle of
mitragynine may mirror that of 7-OH under certain circum-
stances, assuming appropriate dose corrections are made to
account for the eﬃciency of conversion to this active
metabolite in the system under study. It should be mentioned
that during the preparation of this manuscript, other groups
separately reported the formation of 7-OH as a metabolite of
mitragynine in vitro and in rats, but the mechanistic
signiﬁcance of this ﬁnding was not established through
pharmacological studies.38,39 Here we conﬁrmed these
concurrent research ﬁndings and provided the essential in
vivo link demonstrating the pharmacological relevance of 7-
OH.
Our results highlight the critical need to consider metabolic
pathways and interspecies diﬀerences when interpreting
preclinical data on kratom or attempting translation of such
to man. For example, greater or lesser conversion (relative to
mice) of mitragynine to 7-OH in a given species would be
expected to increase or decrease, respectively, the potency of
mitragynine’s opioid activity in that species. At the same time,
if similar metabolic conversion is required for the expression of
opioid agonist activity in humans, there exists the possibility
that metabolic saturation at high doses might provide a built-in
ceiling to the opioid eﬀects of kratom, improving the inherent
safety of this material. In fact, preliminary evidence of such
metabolic saturation can be inferred from the present results,
where the 7-OH brain concentration (0.157 μM) at 15 min
after a high dose (140 mg/kg, s.c.) of mitragynine was only
around sixfold higher than that (0.027 μM) formed from a 14-
fold lower dose (10 mg/kg, s.c.). However, full PK proﬁles at
multiple doses will be needed to conﬁrm the existence of such
a phenomenon. Likewise, metabolic diﬀerences between
individuals will need to be considered, and some individuals
may be more sensitive to the opioid agonist eﬀects of kratom
by virtue of more eﬃcient CYP3A metabolism.
Indeed, here we demonstrated that 7-OH is formed from
mitragynine in HLM and that this conversion appears more
eﬃcient compared to that in MLM. Accordingly, we expect
that 7-OH will also be observed as a metabolite in humans.
This hypothesis is supported by a post-mortem toxicological
Figure 7. 7-OH formed as a metabolite is suﬃcient to explain mitragynine’s analgesic eﬀect in 129S1 mice. (A) Selected doses of mitragynine (140
mg/kg, s.c.) and 7-OH (0.7 mg/kg, s.c.) were equianalgesic at 15 min in the tail-ﬂick assay and induced ∼50% MPE. n = 10 per treatment. Two-
tailed t test, t(18) = 0.66, p = 0.52. ns = p > 0.05. (B) 7-OH was detected in the brains of the same animals at 15 min (sacriﬁce and sample
collection immediately after tail-ﬂick), and there was no diﬀerence in mean brain concentration between the two treatments. n = 9 for mitragynine,
n = 10 for 7-OH. Two-tailed t test, t(17) = 1.19, p = 0.25. ns = p > 0.05. (C) Mitragynine was detected in the brains of the same animals at 15 min,
and there was a signiﬁcant diﬀerence between the two treatments, with a 170-fold higher brain concentration of mitragynine in the animals directly
treated with this drug compared to those treated with 7-OH. n = 10 for mitragynine, n = 6 for 7-OH (four values below the lower limit of
quantitation, 5 ng/g, were excluded from analysis). Two-tailed t test, t(13) = 4.88, p = 0.0003. ***p < 0.001. All bars represent mean ± SEM.
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report from a kratom-associated fatality, where mitragynine
and 7-OH were quantiﬁed in the blood and urine of the
decedent.40 Interestingly, the mitragynine/7-OH ratios found
in blood and urine were ∼7:1 and ∼1.5:1, respectively. It is our
opinion that such high relative concentrations of 7-OH
compared to mitragynine would be impossible to achieve in
the circulation through direct absorption of the minimal
quantities of 7-OH found in kratom leaf preparations and
commercial extracts, where the mitragynine/7-OH ratio is
typically greater than 50:1. Instead, assuming no adulteration
of the ingested material, the high concentrations of 7-OH
observed in this case support the hypothesis that 7-OH is also
formed as an important metabolite in humans. PK studies will
ultimately be required to elucidate the importance of 7-OH as
a mitragynine metabolite in man.
It is interesting to note the apparent parallel of mitragynine
to codeine, a classical opioid that depends on metabolic
conversion to the active metabolite morphine by CYP2D6 for
inducement of opioid eﬀects.41 Accordingly, individuals with
genetic mutations leading to abnormally high or low activity of
CYP2D6 are more or less sensitive to codeine, respectively.41
However, life-threatening respiratory depression with codeine
is rare even in cases of intentional overdose, potentially due to
metabolic saturation.42 Considering that preclinical studies
have found mitragynine to induce less respiratory depression
than codeine,24 which is itself relatively safe compared to other
classical opioids, we hypothesize that severe respiratory
depression or death induced through an opioid mechanism
following oral mitragynine (or kratom) consumption is likely
to be rare. Consistent with this hypothesis, mitragynine has
been found to have low toxicity in mice when administered
orally (LD50 > 400 mg/kg).
31,43 Further, the active metabolite
7-OH has itself been found to be a partial, G protein-biased
agonist at MOR, signaling properties that are hypothesized to
lead to improved respiratory safety among MOR agonists.21,25
Overall, these considerations are consistent with the limited
reports of kratom overdose deaths (44 in total for all time as of
2017, despite millions of worldwide users)14 in comparison to
all opioid overdose deaths (∼50 000 in 2017 alone).44
However, such hypotheses must be conﬁrmed in humans
before deﬁnitive conclusions are reached regarding the
respiratory safety of mitragynine or kratom.
Metabolic processes are also likely to be an important
determinant of the abuse liability of kratom and its alkaloids. It
has recently been found in two independent studies that
mitragynine does not support self-administration (SA) in rats,
while 7-OH is self-administered.45,46 We suspect that this
apparent contradiction may be explained, at least in part, by
the metabolic eﬀects reported here. Mitragynine has been
shown to be more potent (in terms of analgesic eﬀects) in rats
by the p.o. route24 versus the intravenous (i.v.) route used in
the reported self-administration studies, thus complicating
appropriate dose selection and challenging the relevance of i.v.
SA studies for assessing the abuse liability of p.o. mitragynine
(or kratom). Further, the likely necessity of metabolic
conversion of mitragynine to 7-OH for the induction of
opioid agonist eﬀects might result in a temporal dissociation
between drug administration and experience of rewarding
eﬀects, further complicating the interpretation of SA studies.
Lastly, certain individuals with enhanced or deﬁcient CYP3A4
activity may experience greater or lesser reinforcing eﬀects
following mitragynine (or kratom) consumption depending on
the extent of conversion to 7-OH. Again, a comparison to
codeine is warranted, as the abuse liability of this compound
has been found to depend on formation of active metabolites
and vary depending on interindividual diﬀerences in CYP
metabolic eﬃciency.47 There also remains the possibility that
mitragynine exerts a buﬀering eﬀect on the opioid agonist
activity of its 7-OH metabolite, either through direct
competitive antagonism at MOR or through other as-yet-
unknown pharmacological mechanisms. Ultimately, only
controlled clinical trials will be able to deﬁnitively resolve
these issues for mitragynine.
In addition to interspecies metabolic diﬀerences, the in vitro
pharmacology of mitragynine at the opioid receptors is also
species-dependent and complicates the translation of the
present results to humans. For example, we have previously
shown in an in vitro assay that mitragynine acts as a
competitive antagonist at the mMOR but as a weak partial
agonist at the hMOR.21 Accordingly, in humans, mitragynine
itself might contribute to its own analgesic eﬀects directly via
the parent compound, in contrast to the present mouse study,
where most of the analgesic eﬀects appeared to be induced
through the 7-OH metabolite. The interplay between
mitragynine and 7-OH in mediating kratom’s purported
analgesic eﬀects will thus require further exploration in
humans.
Lastly, it is important to mention that extracts of the kratom
plant have been found to both inhibit and induce various CYP
enzymes.48,49 Accordingly, it remains a possibility that the
mixture of compounds contained in the plant or its extracts
may present a distinct opioid pharmacology compared to
isolated mitragynine, by virtue of interference of other
chemical species with the hepatic conversion of mitragynine
to 7-OH. Thus, additional study of metabolic drug−drug
interactions among kratom compounds will also be necessary.
■ CONCLUSION
We have found that the opioid pharmacology of mitragynine is
complicated by the important role of an active metabolite, 7-
OH, in mediating its activity. This apparent requirement for
metabolic activation is consistent with the higher analgesic
potency of mitragynine administered orally versus parenterally
in animals. Further, it suggests a possible explanation for the
seemingly improved safety proﬁle of mitragynine compared to
classical opioid agonists. However, the critical involvement of
hepatic metabolism also complicates our understanding of
mitragynine’s pharmacology and introduces the possibility of
interindividual variability in the compound’s potential
therapeutic eﬀects and side eﬀects. We believe mitragynine
and related compounds have great potential as future
therapeutics, but metabolic processes must be carefully
considered as the ﬁeld continues to advance.
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